Hoe is Sam Lee's beloning veranderd ten opzichte van Cocrystal Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2025	n/a	n/a	-US$10m
Jun 30 2025	n/a	n/a	-US$13m
Mar 31 2025	n/a	n/a	-US$16m
Dec 31 2024	US$681k	US$410k	-US$18m
Sep 30 2024	n/a	n/a	-US$19m
Jun 30 2024	n/a	n/a	-US$18m
Mar 31 2024	n/a	n/a	-US$17m
Dec 31 2023	US$627k	US$395k	-US$18m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$40m
Dec 31 2022	US$622k	US$371k	-US$39m
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$665k	US$333k	-US$14m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$10m
Dec 31 2020	US$462k	US$293k	-US$10m
Sep 30 2020	n/a	n/a	-US$56m
Jun 30 2020	n/a	n/a	-US$55m
Mar 31 2020	n/a	n/a	-US$53m
Dec 31 2019	US$241k	US$241k	-US$48m

Compensatie versus markt: De totale vergoeding ($USD 680.86K ) Sam } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 578.00K ).

Compensatie versus inkomsten: De vergoeding van Sam is gestegen terwijl het bedrijf verliesgevend is.

CEO

Sam Lee (65 yo)

18yrs

Tenure

US$680,859

Compensatie

Dr. Sam Lee, Ph D., Co-founded Cocrystal Pharma, Inc. in 2008 and serves as its President since January 2, 2014 and serves as its Interim Co-Chief Executive Officer since May 2023 and had been its Interim...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Roger Kornberg	Co-Founder	5.8yrs	US$209.97k	0.29% $ 39.5k
Sam Lee	Co-Founder	18yrs	US$680.86k	0.26% $ 36.1k
James Martin	Co-CEO, CFO & Corporate Secretary	8.6yrs	US$680.86k	0.32% $ 43.8k

18.0yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van COCP is doorgewinterd en ervaren (gemiddelde ambtstermijn van 18 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Roger Kornberg	Co-Founder	5.8yrs	US$209.97k	0.29% $ 39.5k
Fred Hassan	Independent Director	2.8yrs	US$50.50k	10.03% $ 1.4m
Richard Pfenniger	Independent Director	4.7yrs	US$50.50k	0.23% $ 31.2k
Phillip Frost	Independent Director	12yrs	US$92.47k	13.45% $ 1.8m
Steven Rubin	Independent Vice Chairman	12yrs	US$115.64k	0.014% $ 1.9k
Michael Levitt	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gary Schoolnik	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Bob Lehman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Roland Strong	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Christophe Verlinde	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Anthony Japour	Independent Director	6.8yrs	US$80.72k	0% $ 0
Baek Kim	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

6.3yrs

Gemiddelde duur

78yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van COCP wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/01/05 21:40
Aandelenkoers aan het einde van de dag	2026/01/02 00:00
Inkomsten	2025/09/30
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Cocrystal Pharma, Inc. wordt gevolgd door 4 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Raghuram Selvaraju	H.C. Wainwright & Co.
Robert LeBoyer	NOBLE Capital Markets, Inc.
David Bautz	Zacks Small-Cap Research

Cocrystal Pharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Independent Director recently bought US$63k worth of stock

Cocrystal Pharma, Inc., Annual General Meeting, Jun 25, 2025

Cocrystal Pharma, Inc., Annual General Meeting, May 18, 2022

Board Member recently sold US$1.7m worth of stock

Board Member notifies of intention to sell stock

Board Member notifies of intention to sell stock

Recent updates

Independent Director recently bought US$63k worth of stock

Cocrystal Pharma, Inc. Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

New major risk - Shareholder dilution

Cocrystal Pharma, Inc. announced that it has received $1.032803 million in funding

Cocrystal Pharma, Inc. Receives NIH SBIR Award to Advance Its Influenza Inhibitor Program

New minor risk - Shareholder dilution

Cocrystal Pharma, Inc. has completed a Follow-on Equity Offering.

Cocrystal Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $7.25 million.

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in A Podium Presentation At the International Calicivirus Conference

Cocrystal Pharma, Inc. Receives Fda Ind Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor Cdi-988, A Potential First Antiviral for Norovirus Prevention and Treatment

Cocrystal Pharma, Inc. Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Cocrystal Pharma, Inc. to Present Data from Phase 1 Study of First-In-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Cocrystal Pharma's Novel Norovirus Antiviral to Be Presented at Department of Defense Medical Conference

Cocrystal Pharma, Inc.'S Investigational Drug Candidate Cc-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5n1 Avian Influenza Strain

Cocrystal Pharma, Inc., Annual General Meeting, Jun 25, 2025

Cocrystal Pharma, Inc.'S Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug Cdi-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

Cocrystal Pharma, Inc. to Extend Phase 2a Influenza Challenge Study with Oral PB2 Inhibitor CC-42344

New major risk - Share price stability

New major risk - Financial position

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Price target decreased by 11% to US$8.00

Cocrystal Pharma, Inc. Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Advances Cc-42344 in Influenza A Phase 2A Study, Expects Topline Results by Late 2024

Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects

Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates

Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast

Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus

Cocrystal Pharma, Inc. Announces Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate Cc-42344

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Consensus forecasts updated

Consensus forecasts updated

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Cocrystal Pharma, Inc. Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

Nasdaq Grants 180 Days to Cocrystal Pharma to Regain Compliance

Price target decreased to US$4.08

Cocrystal Pharma, Inc. Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with Cc-42344, a Novel, Broad-Spectrum Influenza A Antiviral

Cocrystal Pharma, Inc., Annual General Meeting, May 18, 2022

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Price target decreased to US$4.08

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Cocrystal Pharma’s Covid-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful in Vitro Potency Against the Sars-Cov-2 Omicron Variant

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.04 loss per share (vs US$0.046 loss in 3Q 2020)

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Cocrystal Pharma, Inc. Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

CocrystalPharma, Inc ’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

Co-Founder, Chairman & CEO Gary Wilcox has left the company

Board Member recently sold US$1.7m worth of stock

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Cocrystal Pharma, Inc. Provides Update on its COVID-19 Antiviral Discovery and Development Programs

Price target decreased to US$4.50

Full year 2020 earnings released: US$0.17 loss per share (vs US$1.51 loss in FY 2019)

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Board Member notifies of intention to sell stock

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Board Member notifies of intention to sell stock

Cocrystal Pharma Provides Summary of Upcoming Presentation at the Reimagine Health Research Symposium

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck Under Exclusive Worldwide License and Collaboration Agreement

New 90-day high: US$2.19

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

New 90-day high: US$1.71